412051-33-3

Upstream product

• 71666-43-8 2-cyclohexyl-1-(4-hydroxy-phenyl)-ethanone 
• 58987-23-8 2-cyclohexyl-1-(4-methoxyphenyl)ethan-1-one 
• 13154-24-0 triisopropylsilyl chloride 
• 412051-28-6 2-cyclohexyl-1-(4-triisopropylsilyloxy-phenyl)-ethanone 

Downstream Products

• 412051-72-0 2-(5-benzyloxy-2-hydroxy-phenylsulfanyl)-2-cyclohexyl-1-(4-triisopropylsilanyloxy-phenyl)-ethanone 

Relevant academic research and scientific papers

Estrogen receptor ligands. Part 3: The SAR of dihydrobenzoxathiin SERMs

A series of 3-alkyl, 3-cycloalkyl, and 3-heteroaryl dihydrobenzoxathiin analogs 1 were prepared and evaluated for estrogen/anti-estrogen activity in both in vitro and in vivo models. In general, the compounds were found to exhibit a high degree of selectivity for ERα over ERβ, but were less potent than the original lead compound 1a in the inhibition of estradiol-driven uterine proliferation.

Estrogen receptor modulators

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.